<DOC>
	<DOCNO>NCT02746809</DOCNO>
	<brief_summary>The study objectives assess safety efficacy CoreValve Evolut 34R transcatheter aortic valve replacement ( TAVR ) system patient severe symptomatic aortic stenosis consider high extreme risk surgical aortic valve replacement .</brief_summary>
	<brief_title>Medtronic CoreValve Evolut R U.S. Clinical Study ( Evolut 34R Addendum )</brief_title>
	<detailed_description />
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Severe aortic stenosis , define aortic valve area &lt; 1.0 cm2 ( aortic valve area index &lt; 0.6 cm2/m2 ) continuity equation , AND mean gradient &gt; 40 mmHg maximal aortic valve velocity &gt; 4.0 m/sec rest echocardiogram . Subjects lowflow/low gradient severe aortic stenosis include , provide lowdose dobutamine exercise stress echocardiography demonstrate mean gradient &gt; 40 mmHg maximal aortic valve velocity &gt; 4.0 m/sec , AND aortic valve area &lt; 1.0 cm2 ( aortic valve area index &lt; 0.6 cm2/m2 ) . 2 . STS score ≥ 8 OR document heart team agreement ≥ high risk AVR due frailty comorbidities . 3 . Symptoms aortic stenosis , AND NYHA Functional Class II great . 4 . The subject treating physician agree subject return require postprocedure followup visit . 5 . Any condition consider contraindication placement bioprosthetic valve ( e.g . subject indicated mechanical prosthetic valve ) . 6 . A known hypersensitivity contraindication follow adequately premedicated : aspirin heparin ( HIT/HITTS ) bivalirudin ticlopidine clopidogrel Nitinol ( titanium nickel ) contrast medium 7 . Blood dyscrasia define : leukopenia ( WBC &lt; 1000 mm3 ) , thrombocytopenia ( platelet count &lt; 50,000 cells/mm3 ) , history bleed diathesis coagulopathy , hypercoagulable state . 8 . Untreated clinically significant coronary artery disease require revascularization . 9 . Severe leave ventricular dysfunction leave ventricular ejection fraction ( LVEF ) &lt; 20 % echocardiography , contrast ventriculography , radionuclide ventriculography . 10 . End stage renal disease require chronic dialysis creatinine clearance &lt; 20 cc/min . 11 . Ongoing sepsis , include active endocarditis . 12 . Any percutaneous coronary peripheral interventional procedure bare metal drug elute stent perform within 30 day prior study procedure . 13 . Symptomatic carotid vertebral artery disease successful treatment carotid stenosis within 10 week Heart Team assessment . 14 . Cardiogenic shock manifest low cardiac output , vasopressor dependence , mechanical hemodynamic support . 15 . Recent ( within 6 month Heart Team assessment ) cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) . 16 . Gastrointestinal ( GI ) bleed would preclude anticoagulation . 17 . Subject refuse blood transfusion . 18 . Severe dementia ( result either inability provide inform consent study/procedure , prevents independent lifestyle outside chronic care facility , fundamentally complicate rehabilitation procedure compliance followup visit ) . 19 . Estimated life expectancy le 12 month due associate noncardiac comorbid condition . 20 . Other medical , social , psychological condition opinion investigator precludes subject appropriate consent adherence protocol require followup exam . 21 . Currently participate investigational drug another device study ( exclude registry ) . 22 . Evidence acute myocardial infarction ≤ 30 day study procedure . 23 . Need emergency surgery reason . 24 . Liver failure ( ChildPugh class C ) . 25 . Subject pregnant breast feeding . Anatomical exclusion criterion : 26 . Preexisting prosthetic heart valve position . 27 . Mixed aortic valve disease ( aortic stenosis severe aortic regurgitation ) . 28 . Severe mitral regurgitation . 29 . Severe tricuspid regurgitation . 30 . Moderate severe mitral stenosis . 31 . Hypertrophic obstructive cardiomyopathy . 32 . Echocardiographic MultiSlice Computed Tomography ( MSCT ) evidence intracardiac mass , thrombus , vegetation . 33 . Congenital bicuspid unicuspid valve verify echocardiography . For transfemoral transaxillary ( subclavian ) access : 34 . Access vessel diameter &lt; 5.5 mm &lt; 6.0 mm patent LIMA</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>